{
    "organizations": [],
    "uuid": "9e580369ee9f8c840565cfec48797662cbabc34d",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-dar-bioscience-enters-into-exclusi/brief-dar-bioscience-enters-into-exclusive-worldwide-license-agreement-for-juniper-pharmaceuticals-intravaginal-ring-technology-platform-idUSFWN1S20RR",
    "ord_in_thread": 0,
    "title": "BRIEF-Daré Bioscience Enters Into Exclusive Worldwide License Agreement For Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - Dare Bioscience Inc:\n* DARÉ BIOSCIENCE, INC. ENTERS INTO EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR JUNIPER PHARMACEUTICALS’ INTRAVAGINAL RING (IVR) TECHNOLOGY PLATFORM\n* DARE BIOSCIENCE INC - SECURED EXCLUSIVE LICENSE TO JUNIPER PHARMACEUTICALS’ INTRAVAGINAL RING TECHNOLOGY, INCLUDING JUNIPER’S 3 PRECLINICAL CANDIDATES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-25T20:10:00.000+03:00",
    "crawled": "2018-04-26T20:53:37.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "dare",
        "bioscience",
        "inc",
        "daré",
        "bioscience",
        "enters",
        "exclusive",
        "worldwide",
        "license",
        "agreement",
        "juniper",
        "pharmaceutical",
        "intravaginal",
        "ring",
        "ivr",
        "technology",
        "platform",
        "dare",
        "bioscience",
        "inc",
        "secured",
        "exclusive",
        "license",
        "juniper",
        "pharmaceutical",
        "intravaginal",
        "ring",
        "technology",
        "including",
        "juniper",
        "preclinical",
        "candidate",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}